Biopartnering Seminar Series - "Dex" - By Future Digital Agents
Abstract: Alzheimer’s Disease (AD) and related dementia affects 50 million people worldwide, with 5.8 million Americans currently diagnosed with AD and cases expected to reach 14 million by 2050. Agitation is the one of the most commonly reported symptoms (up to 70% of dementia cases), leading to heightened caregiver stress, premature patient institutionalization, and increased cost of care. Standard treatment currently includes antipsychotics, which are usually prescribed off-label and have “black box warnings” due to their adverse side effects in elderly populations. BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company focused on drug development that utilizes artificial intelligence, is currently developing a new treatment for acute agitation in people with dementia: a proprietary sublingual film BXCL-501 of the drug dexmedetomidine (“Dex”). As no current FDA approved treatments for agitation exist, this provides an attractive opportunity for targeting AD management. The drug will be used in combination with a wearable performing real-time monitoring of patient biometrics and employing machine learning to predict the onset of an agitation event. The goal is to improve treatment regimens through informed administration of Dex prior to the event as well as prevent or mitigate the severity of agitation in these patients. Key considerations and potential barriers for this approach were identified, including target market profile, wearable device design and adoption by caregivers and nurses. We recommend targeting dementia patients in nursing homes specializing in memory care and incorporating the algorithm into the Apple Watch. To explore additional issues, we propose a pre-market qualitative research study for this novel combination therapy for AD patients in long-term care homes.
Warning: zoom bomb at ~54'